Ibogaine in the Treatment of Alcoholism: a Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial

This phase II, escalating-dose study tests oral ibogaine in people with alcohol use disorder; an initial open-label lead-in (first 3 participants, 20–400 mg) precedes a randomized placebo-controlled allocation for the remaining participants.

Participants are hospitalised for 20 days, receive three escalating doses (examples: 240, 320, 400 mg) and are followed at 7, 14, 21 days and 1, 3, 6, 12 months for alcohol and other drug use and safety monitoring.